Skip to main content
SpringerLink
Log in

Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The relationship between tumor proliferative activity and response to first-line chemotherapy and survival was investigated in 76 advanced breast cancer patients. Proliferative activity was determined by means of Ki-67 immunohistologic staining on primary tumors (55 patients) or at the relapse site (21 patients), and was classified as low (≤ 25% of stained cells) or high (> 25% of stained cells). The usual WHO response criteria were used. The median duration of follow-up was 18 months (range 3–58).

Forty-seven patients (62%) had tumors with low, and 29 (38%) had tumors with a high rate of proliferative activity. The two groups were well balanced in terms of important variables such as disease-free survival, performance status, age, menopausal status, and the type of first-line chemotherapy (anthracycline-based regimens versus cyclophosphamide-methotrexate-5-fluorouracil). The estrogen receptor (ER) content, measured by means of immunohistochemical assay, was markedly different in the two groups, with 27/47 tumors with low proliferative activity (57%) and 6/29 with high-proliferative activity (21%) being ER positive (≥ 45% of stained cells) (p = 0.003). Moreover, a significant difference in the metastatic pattern was also evident, with a higher incidence of bone and a lower incidence of soft tissue metastases in the group of patients with tumors with low proliferative activity (p = 0.004). Overall, 10/47 responses (21%: PR = 7, and CR = 3) were observed in the group with a low rate of proliferative activity, versus 14/29 (48%: PR = 9, and CR = 5) in the group with highly proliferative tumors, the difference being statistically significant (p = 0.03). When a multivariate analy-sis was performed, the only factor that retained independent prognostic significance was the predominant site of disease, particularly soft tissues (p = 0.003). Despite the difference in response rate, when survival analysis was performed according to the Kaplan-Meier method, no significant difference was observed in the two groups, but when the analysis was limited to responsive patients, the median survival observed in those with a low and those with a high rate of proliferation was 35 and 19 months respectively (p = 0.02). The same results were obtained when multivariate survival analysis was carried out using Cox's regression model. These data suggest that there is a link between tumor proliferative activity and response to chemotherapy in advanced breast cancer, and may indicate the need to use more intensive treatments in selected patients with highly proliferative tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Tubiana M: Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol 28: 113–121, 1988

    Google Scholar 

  2. Mendelsohn ML: The growth fraction: a new concept applied to tumors. Science 132: 1496, 1960

    Google Scholar 

  3. Tubiana M, Malaise EP: Comparison of cell proliferation kinetics in human and experimental tumors: response to irradiation. Cancer Treat Rep 60: 1887–1895, 1976

    PubMed  Google Scholar 

  4. Quinn CM, Wright NA: The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol 160: 93–102, 1990

    PubMed  Google Scholar 

  5. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13–20, 1983

    PubMed  Google Scholar 

  6. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715, 1984

    PubMed  Google Scholar 

  7. Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H: Growth fractions in malignant non-Hodgkin lymphomas (NHL) as determinedin situ with the monoclonal antibody Ki-67. Hemathol Oncol 2: 365–371, 1984

    Google Scholar 

  8. Kamel OW, Franklin WA, Ringus JC, Meyer JS: Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol 134: 107–113, 1989

    PubMed  Google Scholar 

  9. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW, Nicholson RI: Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59: 943–947, 1989

    PubMed  Google Scholar 

  10. Deshmukh P, Ramsey L, Garewal HS: Ki-67 labeling index is a more reliable measure of solid tumor proliferative activity than tritiated thymidine labeling. Am J Clin Pathol 94: 192–195, 1990

    PubMed  Google Scholar 

  11. Vielh P, Chevillard S, Mosseri V, Donatini B, Magdelenat H: Ki-67 index and S-phase fraction in human breast carcinomas. Comparison and correlation with prognostic factors. Am J Pathol 94: 681–686, 1990

    Google Scholar 

  12. Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa APM, Calderini P, Liscia DS: Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer 29A: 1509–1513, 1993

    PubMed  Google Scholar 

  13. Henderson IC, Garber JE, Breitmeyer JB, Hayes DF, Harris JR: Comprehensive management of disseminated breast cancer. Cancer 66: 1439–1448, 1990

    PubMed  Google Scholar 

  14. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981

    PubMed  Google Scholar 

  15. Gerdes J, Pickartz H, Brotherton J, Hammerstein J, Weitzel H, Stein H: Growth fractions and estrogen receptors in human breast cancers as determinedin situ with monoclonal antibodies. Am J Pathol 129: 486–492, 1987

    PubMed  Google Scholar 

  16. Pertschuk LP, Eisenberg KB, Carter AC, Feldman JG: Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Cancer 55: 1513–1518, 1985

    PubMed  Google Scholar 

  17. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, Sperotto L, Martignoni G, Bonetti A, Nortilli R, Castelli P, Rodella S, Capelli P, Manfrin E, Pelosi G, Cetto GL: Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 34: 221–228, 1995

    PubMed  Google Scholar 

  18. Fleiss LJ: Assessing significance in a fourfold table. In: Fleiss LJ (ed) Statistical Methods for Rates and Proportions. John Wiley & Sons, New York, 1981, pp 19–32

    Google Scholar 

  19. Hosmer DW, Lemeshow S: Applied Logistic Regression. John Wiley & Sons, New York, 1989

    Google Scholar 

  20. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–461, 1958

    Google Scholar 

  21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170, 1966

    PubMed  Google Scholar 

  22. Campos-Filho N, Franco EL: COXSURV: a microcomputer program for multiple regression by Cox proportional hazards model. Comp Meth Prog Biomed 31: 81–87, 1990

    Google Scholar 

  23. SAS Institute Inc. SAS Guide for Personal Computers, version 6.03. SAS Institute Inc., Cary, NC

  24. Campos-Filho N, Franco EL: KMSURV: a microcomputer program for univariate survival data analysis. Comp Meth Prog Biomed 27: 223–228, 1988

    Google Scholar 

  25. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926–3931, 1993

    PubMed  Google Scholar 

  26. Wintzer HO, Zipfel I, Schulte-Mönting J, Hellerich U, von Kleist S: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67: 421–428, 1991

    PubMed  Google Scholar 

  27. Sahin AA, Jungsil R, Jae YR, Blick MB, El-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG: Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Cancer 68: 549–557, 1991

    PubMed  Google Scholar 

  28. Weikel W, Beck T, Mitze M, Knapstein PG: Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149–154, 1991

    PubMed  Google Scholar 

  29. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25: 1165–1171, 1989

    PubMed  Google Scholar 

  30. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Mariani L, Bonadonna G:3H-thimidine-labeling index as a prognostic indicator in node-positive breast cancer. J Clin Oncol 8: 1321–1326, 1990

    PubMed  Google Scholar 

  31. Muss HB, Kute TE, Case D, Smith LR, Booher C, Long R, Kammire L, Gregory B, Brockschmidt JK: The relationship of flow cytometry to clinical and biologic characteristics in women with node-negative primary breast cancer. Cancer 64: 1894–1900, 1989

    PubMed  Google Scholar 

  32. O'Reilly SM, Camplejohn DM, Barnes DM, Millis RR, Rubens RD, Richards MA: Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 8: 2040–2046, 1990

    PubMed  Google Scholar 

  33. Clark GM, Dressler LG, Owens MR, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627–633, 1989

    PubMed  Google Scholar 

  34. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383–1387, 1989

    PubMed  Google Scholar 

  35. O'Reilly SM, Camplejohn RS, Rubens RD, Richard MA: DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 28: 681–683, 1992

    PubMed  Google Scholar 

  36. Gardin G, Alama A, Rosso R, Campora E, Repetto L, Pronzato P, Merlini L, Naso C, Camoriano A, Meazza R, Barbieri F, Baldini E, Giannessi PG, Conte PF: Relationship of variations in cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treat 32: 311–318, 1994

    PubMed  Google Scholar 

  37. Sulkes A, Livingston RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62: 513–515, 1979

    PubMed  Google Scholar 

  38. Weiss LM, Strickler JG, Medeiros LJ, Gerdes J, Stein H, Warnke RA: Proliferative rates of non-Hodgkin lymphomas as assessed by Ki-67 antibody. Hum Pathol 18: 1155–1159, 1987

    PubMed  Google Scholar 

  39. Diamond LW, Bharat NN, Rappaport H: Flow cytometry in the diagnosis and classification of malignant lymphoma and leukemia. Cancer 50: 1122–1135, 1982

    PubMed  Google Scholar 

  40. Korkolopoulou P, Patsouris E, Pangalis G, Tsenga A, Elemenoglou J, Thomas-Tsangali E, Spandidos D, Kittas C: A comparative assessment of proliferating cell nuclear antigen, c-myc p62, and nucleolar organizer region staining in non-Hodgkin lymphomas: a histochemical and immunohistochemical study of 200 cases. Human Pathol 24: 371–377, 1993

    Google Scholar 

  41. Cowan RA, Harris M, Jones M, Crowther D: DNA content in high and intermediate grade non-Hodgkin's lymphoma — prognostic significance and clinico-pathological correlations. Br J Cancer 60: 904–910, 1989

    PubMed  Google Scholar 

  42. Grierson HL, Wooldridge TN, Purtilo DT, Pierson J, Bast M, Wooldridge L, Armitage JO, Weisenburger DD: Low proliferative activity is associated with a favorable prognosis in peripheral T-cell lymphoma. Cancer Res 50: 4845–4848, 1990

    PubMed  Google Scholar 

  43. Silvestrini S, Costa A, Boracchi P, Giardini R, Rilke F: Cell proliferation as a long-term prognostic factor in diffuse large-cell lymphomas. Int J Cancer 54: 231–236, 1993

    PubMed  Google Scholar 

  44. Miller TP, Grogan TM, Dahlberg S, Spier MC, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, Schnitzer B, Tubbs RR, Gaynor ER, Fisher RI: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin lymphomas: a prospective Southwest Oncology Group trial. Blood 83: 1460–1466, 1994

    PubMed  Google Scholar 

  45. Williamson JMS, Grigor I, Smith MEF, Holgate CS, O'Brien CJ, Morgan DR, Quirke P, Alison DL, Child JA, Bird CC: Ploidy, proliferative activity, cluster differentiation, antigen expression and clinical remission in high-grade non-Hodgkin lymphoma. Histopathology 11: 1043–1054, 1987

    PubMed  Google Scholar 

  46. Silvestrini R, Daidone MG, Bertuzzi A, Di Fronzo G: Relationship between estrogen receptors and cellular proliferation. Recent Results Cancer Res 91: 163–168, 1984

    PubMed  Google Scholar 

  47. Gasparini G, Dal Fior S, Pozza F, Bevilacqua P: Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. Breast Cancer Res Treat 14: 329–336, 1989

    PubMed  Google Scholar 

  48. Silvestrini R, Daidone MG, Del Bino G, Mastore M, Luisi A, Di Fronzo G, Boracchi P: Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol 4: 213–219, 1993

    PubMed  Google Scholar 

  49. Di Stefano D, Mingazzini P, Scucchi L, Donnetti M, Marinozzi V: A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining and nucleolar organizer region-associated proteins in human breast cancer. Cancer 67: 463–471, 1991

    PubMed  Google Scholar 

  50. Veronese SM, Gambacorta M: Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol 95: 30–34, 1991

    PubMed  Google Scholar 

  51. Meyer JS, McDivitt RW: Reliability and stability of the thymidine labeling index of breast carcinoma. Lab Invest 54: 160–164, 1986

    PubMed  Google Scholar 

  52. Meyer JS, Lee JY: Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res 40: 1890–1896, 1980

    PubMed  Google Scholar 

  53. Silvestrini R, Valentinis B, Daidone MG, Di Fronzo G, Coradini D, Salvadori B: Biological characterisation of primary and methacronous lesions in breast cancer. Eur J Cancer 28A: 2006–2010, 1992

    PubMed  Google Scholar 

  54. Harris JR, Morrow M, Bonadonna G: Cancer of the breast. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology (ed 4). Lippincott, Philadelphia, 1993, pp 1264–1332

    Google Scholar 

  55. Smets LA: Programmed cell death (apoptosis) and response to anti-cancer drugs. Anti-Cancer Drugs 5: 3–9, 1994

    PubMed  Google Scholar 

  56. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C, Hickman J: bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53: 3321–3326, 1993

    PubMed  Google Scholar 

  57. Goldie JH: Drug resistance. In: Perry MC (ed) The Chemotherapy Source Book. Williams & Wilkins, Baltimore, 1992, pp 54–66

    Google Scholar 

  58. Armitage JO: Tumor proliferative rate and response to chemotherapy. Ann Int Med 116: 771–773, 1992

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Department of Medical Oncology and Pathology, Civic Hospital of Borgo Trento and University of Verona, Ple Stefani 1, 37121, Verona, Italy

    Andrea Bonetti, Marta Zaninelli, Stefania Rodella, Annamaria Molino, Loris Sperotto, Quirino Piubello, Franco Bonetti, Rolando Nortilli, Monica Turazza & Gian Luigi Cetto

Authors
  1. Andrea Bonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marta Zaninelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefania Rodella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annamaria Molino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Loris Sperotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Quirino Piubello
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Franco Bonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rolando Nortilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Monica Turazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gian Luigi Cetto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonetti, A., Zaninelli, M., Rodella, S. et al. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res Tr 38, 289–297 (1996). https://doi.org/10.1007/BF01806148

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806148

Key words

Search

Navigation